IPCS framework for analyzing the relevance of a cancer mode of action for humans.
about
Cumulative risk assessment (CRA): transforming the way we assess health risksIPCS framework for analyzing the relevance of a noncancer mode of action for humansCritical role of toxicologic pathology in a short-term screen for carcinogenicityComparison of toxicogenomics and traditional approaches to inform mode of action and points of departure in human health risk assessment of benzo[a]pyrene in drinking waterEvaluation of carcinogenic modes of action for pesticides in fruit on the Swedish market using a text-mining toolIdentifying an indoor air exposure limit for formaldehyde considering both irritation and cancer hazardsDeveloping and applying the adverse outcome pathway concept for understanding and predicting neurotoxicityAssessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humansCurrent understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessmentAssessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge aheadGenomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of actionImproving weight of evidence approaches to chemical evaluations.Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework.Scientific and Regulatory Policy Committee (SRPC) Review: Interpretation and Use of Cell Proliferation Data in Cancer Risk Assessment.A data-based assessment of alternative strategies for identification of potential human cancer hazards.The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides.Systems Toxicology: Real World Applications and Opportunities.Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activatorApplication of key events analysis to chemical carcinogens and noncarcinogensThe Key Events Dose-Response Framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds.Investigating alternatives to the fish early-life stage test: a strategy for discovering and annotating adverse outcome pathways for early fish developmentAlternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.Evaluation of the carcinogenicity of inorganic arsenic.Glyphosate toxicity and carcinogenicity: a review of the scientific basis of the European Union assessment and its differences with IARC.Adverse outcome pathway (AOP) development I: strategies and principlesAdverse outcome pathway development II: best practices.Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence.An organizational approach for the assessment of DNA adduct data in risk assessment: case studies for aflatoxin B1, tamoxifen and vinyl chloride.Toxicology and epidemiology: improving the science with a framework for combining toxicological and epidemiological evidence to establish causal inferencePredicting the future: opportunities and challenges for the chemical industry to apply 21st-century toxicity testing.Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findingsIdentification and characterization of adverse effects in 21st century toxicologyRelationship of metabolism and cell proliferation to the mode of action of fluensulfone-induced mouse lung tumors: analysis of their human relevance using the IPCS framework.Trend of cancer risk of Chinese inhabitants to dioxins due to changes in dietary patterns: 1980-2009Building shared experience to advance practical application of pathway-based toxicology: liver toxicity mode-of-action.Thiazopyr and thyroid disruption: case study within the context of the 2006 IPCS Human Relevance Framework for analysis of a cancer mode of action.Consideration of rat chronic progressive nephropathy in regulatory evaluations for carcinogenicity.Contributions of DNA repair and damage response pathways to the non-linear genotoxic responses of alkylating agents.Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties.State-of-the-science workshop report: issues and approaches in low-dose-response extrapolation for environmental health risk assessment.
P2860
Q23919124-83A1B3A4-2F20-4762-95AF-94DC34CB15D0Q27921844-AA1F9833-F778-4A15-B6AB-C305E6B89E78Q28075960-F7371F17-7A3E-4D3D-9A49-DAA208B5440AQ28384756-25C1F25C-AFB6-4C2A-B3C7-5FD6F31EEBCAQ28388427-A45C04C7-8FDD-4A75-A1DD-D9DD47E98B2BQ28392001-51A0E239-9044-41F6-9897-CCD361543401Q28394433-324902AE-4864-47EE-9D2C-EEB02142B34AQ28396010-8A6EEFB5-58A9-4D0C-BAA9-201A9F93674EQ28396265-D1738358-C1EC-421E-B575-85F55274EEABQ28397132-EDEC06C8-4F8E-440B-8D4E-2BF3186A581BQ28541142-0AA66ECE-DDF4-4F73-A4FE-F5418EA1790AQ30301106-B989CADF-6855-43EC-91C1-3970275E5FFFQ30662351-85D1A1C7-B255-40FD-B7BA-BF8047223743Q30938639-C0C40F00-C113-42F5-933C-B63CF8A85A01Q33495954-FBC83D3A-8AE0-411D-8D81-1E447A329EE2Q33530406-422CE5CB-D6B1-4CED-9AAE-E82AFF588367Q33577370-C0B86538-667A-4089-9CDC-AD55C318AADDQ33606444-7C552E39-3AB7-454C-B9DF-BCBB82681B16Q33736229-E85CB03D-D6B2-4B32-9F11-45F42096057FQ33736240-22EAC6FC-58C6-4FC9-9C0B-64C675B97902Q33989642-A6FFFDED-1D2D-4EC8-A2B0-626446B50E41Q34181630-52C75D3B-1274-44F9-B5FC-95B966723FF3Q34371580-A20B9F44-97BA-4FE0-99FF-B0A87070EC6AQ34554675-34F1B5B0-37CD-4834-85FC-8113EF077B2EQ35055206-D1A4C08C-A34D-4640-ABE8-D37C210C0601Q35055209-EC2EA16B-F386-4530-8A41-C321549581C7Q35062017-740484AE-A203-4ED2-B9D7-025C7E9B3D93Q35086803-E0CF403F-1CC4-45AA-8E75-E56B25938FF4Q35161424-0EB58271-504E-493A-B73D-429F62D233E9Q35244698-4E20E351-5631-47FA-A8AD-A3E1D9C9F652Q35603973-CC073D9F-FF2F-44E7-B051-7D380BD4F221Q35839538-686DDB66-6358-48F0-BBFD-B21BB80A9CB2Q36080030-1401BEF7-7042-49BD-88DD-7A7A4D473956Q36615892-D22297EE-9B07-4736-9A46-937500822515Q36655325-65E239AF-132B-40D5-9B5A-A8F172B0BDABQ36659779-C69E0EF4-81E1-4B4C-9F11-3314DA4A2B89Q36678470-E5475DE2-63B3-4856-8AD3-5EA6E94214B5Q36759955-F552CDFA-ADB0-4E64-A4B1-562883F01F1DQ37008642-4A3AE183-BB03-4202-8BDD-9DD9A7951863Q37112553-974C3EEF-0284-43AA-A425-4349B326D4C4
P2860
IPCS framework for analyzing the relevance of a cancer mode of action for humans.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
IPCS framework for analyzing the relevance of a cancer mode of action for humans.
@en
IPCS framework for analyzing the relevance of a cancer mode of action for humans.
@nl
type
label
IPCS framework for analyzing the relevance of a cancer mode of action for humans.
@en
IPCS framework for analyzing the relevance of a cancer mode of action for humans.
@nl
prefLabel
IPCS framework for analyzing the relevance of a cancer mode of action for humans.
@en
IPCS framework for analyzing the relevance of a cancer mode of action for humans.
@nl
P2093
P2860
P1476
IPCS framework for analyzing the relevance of a cancer mode of action for humans.
@en
P2093
Carolyn Vickers
Deborah Willcocks
Douglas McGregor
M E Bette Meek
Samuel M Cohen
Vicki Dellarco
William Farland
P2860
P304
P356
10.1080/10408440600977677
P407
P577
2006-11-01T00:00:00Z